Serplulimab immunotherapy

Phase 2Small molecule

FFirst Affiliated Hospital of Wenzhou Medical University

Serplulimab immunotherapy is one of 29 small molecule programs targeting Rectal Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Rectal CancerRecruiting

Rectal CancerPhase 2

Recruiting

Competition

Competitive Landscape

33 competitors in Rectal Cancer

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 3

21 2

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

27 3

Adrucil

EElorac, Inc.

Phase 3

6 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Phase 3

5 5

Capeox

GSK

Phase 3

2 6

Stivarga

Bayer

Phase 2

2 7

Keytruda

Merck & Co.

Phase 2

2 8

Opdivo

Bristol-Myers Squibb

Phase 2

1 9

Tukysa

Pfizer

Phase 2

1 10

PD-1

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 2Recruiting

Rectal Cancer

NCT07347951

Clinical

Trials by Indication[1]

Rectal Cancer1 trial

A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer

Recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07347951·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Serplulimab immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Serplulimab immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Serplulimab immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — First Affiliated Hospital of Wenzhou Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: FFirst Affiliated Hospital of Wenzhou Medical University

Serplulimab immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

Rectal Cancer1 trial

References

Drug Info

Quick Facts

Related News